Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loose Regulatory Standards Portend a New Era of Imprecision Oncology.

Cancer investigation - 1 Feb 2021

Khaki Ali Raza

Abstract excerpt

Precision oncology has revolutionized the therapeutic landscape of oncology and is a goal for cancer drug development. However, lenient drug approvals by the United States Food and Drug Administration under the auspices of precision oncology are setting up this therapeutic approach to fail. In this commentary, I review two recent FDA drug approvals (pembrolizumab for tumor mutation burden-high solid tumors and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Drug Approval
Share to Phthalazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Precision Medicine

Share to Prostatic Neoplasms, Castration-Resistant

Share to United States

Share to United States Food and Drug Administration

Source

Open in PubMed Open full text

Identifiers

PMID: 33290099
DOI: 10.1080/07357907.2020.1851705
PMCID: PMC7875517

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loose Regulatory Standards Portend a New Era of Imprecision Oncology.PMID 33290099Read ↗

The Future of Precision Oncology.Semantic proximity Read ↗

Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future PerspectivesSemantic proximity Read ↗

Precision Oncology: Who, How, What, When, and When Not?Semantic proximity Read ↗

Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted TherapiesSemantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticsSemantic proximity Read ↗

Precision oncology: separating the wheat from the chaffSemantic proximity Read ↗

Enabling Precision Oncology Through Precision DiagnosticsSemantic proximity Read ↗

Precision oncology: A new era of cancer clinical trialsSemantic proximity Read ↗

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.Semantic proximity Read ↗

Precision oncology: where next?Semantic proximity Read ↗

Top advances of the year: Precision oncology.Semantic proximity Read ↗

Precision Oncology: Between Vaguely Right and Precisely Wrong.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.